The Mepolizumab Market: A New Era in Targeted Respiratory Therapy

Tue, 18 Nov 2025 11:32:50 +0000

Asthma has long been a global health burden, affecting millions with symptoms that range from mild discomfort to life-threatening attacks. For a significant subset of patients, particularly those with severe eosinophilic asthma, conventional inhalers and steroids offered limited relief and came with a heavy burden of side effects. The landscape of severe asthma treatment, however, has been fundamentally reshaped by the advent of biologic therapies. At the forefront of this revolution is mepolizumab, a precision-engineered monoclonal antibody that has carved out a substantial and growing segment within the global pharmaceutical market. This post delves into the dynamics of the mepolizumab market, exploring its scale, key players, growth drivers, and the challenges that lie ahead.